Comparison · NCT04703075-sae
Arm A: 1HP vs Arm B: 3HP: serious adverse events
Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.
2 sourcestrial-comparisons-2026-03-23-0.1.0
Cite this record
ConductScience Library. Arm A: 1HP vs Arm B: 3HP: serious adverse events. Trial comparisons, record NCT04703075-sae. Release trial-comparisons-2026-03-23-0.1.0, 23 Mar 2026. https://conductscience.org/library/comparisons/NCT04703075-sae
On this page
Measures6
Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.
| Measure | Value | 95% interval, lower | 95% interval, upper | Method | Note |
|---|---|---|---|---|---|
| Risk in group 1 | 0.00402 | 0.000709 | 0.0224 | wilson | |
| Risk in group 2 | 0.00797 | 0.00219 | 0.0286 | wilson | |
| Risk difference, group 1 minus group 2 | -0.00395 | -0.0248 | 0.0153 | newcombe hybrid score | |
| Risk ratio, group 1 over group 2 | 0.504 | 0.046 | 5.52 | log | |
| Odds ratio, group 1 over group 2 | 0.502 | 0.0452 | 5.57 | log | |
| Number needed to treat, for one fewer participant with a serious adverse event on Arm A: 1HP than on Arm B: 3HP | 253 | from the risk difference interval | the interval includes no difference |
Source ClinicalTrials.gov
Groups2
Neither group, or both, names a comparator, so the groups keep ClinicalTrials.gov's order.
| Group | Title | Description | With the outcome | Analysed | ClinicalTrials.gov code |
|---|---|---|---|---|---|
| Group 1 | Arm A: 1HP | Participants will receive Rifapentine 600 mg daily and isoniazid (INH) 300 mg daily for 4 weeks.~Rifapentine 600 mg and INH 300 mg: Participants will receive Rifapentine 600 mg and INH 300 mg | 1 | 249 | EG000 |
| Group 2 | Arm B: 3HP | Participants will receive Rifapentine 900 mg and isoniazid 900 mg weekly for 12 weeks.~Rifapentine 900 mg and INH 900 mg: Participants will receive Rifapentine 900 mg and INH 900mg | 2 | 251 | EG001 |
Source ClinicalTrials.gov
Harm
- What it counts
- Total, serious adverse events
- Time frame
- Up to 6 months
Source ClinicalTrials.gov
Trial
- Title
- Ultra Curto (Ultra Short) TB Prevention Therapy
- NCT number
- NCT04703075
- Phases
- PHASE4
- Conditions
- Tuberculosis
- Interventions
- Rifapentine 600 mg and INH 300 mg, Rifapentine 900 mg and INH 900 mg
- Lead sponsor
- Johns Hopkins University
- Results first posted
- 2025-06-19
- Results on ClinicalTrials.gov
- https://clinicaltrials.gov/study/NCT04703075?tab=results
Source ClinicalTrials.gov
Source
- Release
- trial-comparisons-2026-03-23-0.1.0
- Release manifest SHA-256
- f66225897fbf258b57ea10bdacfd0347d3cdfda93f7f5685234b7e06ea36fa57
- AACT copy
- 2026-03-23
- Tables read
- outcome_counts.parquet, outcome_measurements.parquet, outcomes.parquet, reported_event_totals.parquet, reported_events.parquet, result_groups.parquet, studies.parquet, ctgov_trial.parquet
Source ClinicalTrials.gov
Sources 2
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions. The measures are ConductScience's calculation from them.
For software
Read this comparison from software.
The record is JSON. No key.
GET https://conductscience.org/api/comparisons/v1/NCT04703075-sae